Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Se-Hoon Lee, June-Koo Lee, Myung-Ju Ahn, Dong-Wan Kim, Jong-Mu Sun, Bhumsuk Keam, Tae Min Kim, Dae Seog Heo, Jin Seok Ahn, Yoon-La Choi, Hae-Sook Min, Yoon-Kyung Jeon, Keunchil Park | ||||||||||||
Title | A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/166941-176 | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 9013) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET fusion | lung non-small cell carcinoma | sensitive | Vandetanib | Phase II | Actionable | In a Phase II trial, Caprelsa (vandetanib) treatment resulted in partial remission in 17% (3/18) and stable disease in 44% (8/18) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9013)). | detail... |